New Zealand markets close in 3 hours 7 minutes
  • NZX 50

    11,338.94
    +71.55 (+0.64%)
     
  • NZD/USD

    0.6452
    +0.0042 (+0.66%)
     
  • NZD/EUR

    0.6092
    +0.0030 (+0.50%)
     
  • ALL ORDS

    7,428.70
    +37.70 (+0.51%)
     
  • ASX 200

    7,176.40
    +30.80 (+0.43%)
     
  • OIL

    111.05
    +0.77 (+0.70%)
     
  • GOLD

    1,850.20
    +8.10 (+0.44%)
     
  • NASDAQ

    11,835.62
    -39.98 (-0.34%)
     
  • FTSE

    7,389.98
    +87.24 (+1.19%)
     
  • Dow Jones

    31,261.90
    +8.80 (+0.03%)
     
  • DAX

    13,981.91
    +99.61 (+0.72%)
     
  • Hang Seng

    20,572.77
    -144.47 (-0.70%)
     
  • NIKKEI 225

    26,973.87
    +234.84 (+0.88%)
     
  • NZD/JPY

    82.2040
    +0.2720 (+0.33%)
     

Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™

·2-min read

- Presentations Include Initial First-in-Human Data on Lead Candidate AZ-3102 in Healthy Volunteers -

LEIDEN, The Netherlands, January 18, 2022--(BUSINESS WIRE)--Azafaros B.V. today announced its participation at the 18th Annual WORLDSymposium, a research conference dedicated to lysosomal storage diseases, taking place from February 7 – 11, 2022, in San Diego, CA. The conference is also offering virtual participation. Azafaros will share first-in-human data on its lead candidate AZ-3102, a novel orally available azasugar molecule with a unique dual mode of action, as well as the design for a natural history study in GM1 and GM2 gangliosidosis and preclinical in vivo data on AZ-3102 in Niemann-Pick and Sandhoff disease mouse models.

Details on the presentations are as follows:

Title: A first-in-human, randomized, double-blind, placebo-controlled, ascending single- and multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the L-ido azasugar AZ-3102 in healthy volunteers; Virtual Poster LB- 54.
Presenter: Cecile Paquet Luzy
Date & Time: Wednesday February 9 from 3:00 – 5:00 pm Pacific Time (PT)

Title: Prospective longitudinal study of neurological disease trajectory in children living with late infantile or juvenile onset of GM1 or GM2 gangliosidosis (PRONTO study); In Person Poster 98.
Presenter: Roberto Giugliani
Date & Time: Wednesday February 9, from 3:00 – 5:00 pm PT

Title: Characterization of AZ-3102, a novel brain-penetrant small molecule, in the Niemann-Pick disease type C mouse model; Contemporary Forum Platform Presentation, Poster 161.
Presenter: Kyle Landskroner
Date & Time: Thursday, February 10 at 2:00 pm PT

Title: AZ-3102, a novel brain-penetrant small molecule, significantly improves survival of Sandhoff disease mice; Late-Breaking Science Platform Presentation, Poster LB-70
Presenter: Jagdeep Walia
Date & Time: Friday February 11 at 11:15 am PT

The posters will be available on the Azafaros website following presentation at the WORLDSymposium™ conference.

About Azafaros
Founded in 2018 with a deep understanding of rare genetic disease mechanisms and led by a team of highly experienced industry experts, Azafaros aims to build a pipeline of disease-modifying therapeutics to offer patients and their families new treatment options. The company’s lead clinical-staged program is AZ-3102, a highly differentiated, orally available, small molecule with the potential to treat GM1 and GM2 gangliosidosis and other metabolic disorders. By applying its know-how, network, and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005284/en/

Contacts

For further information:
Azafaros B.V.
Email: info@azafaros.com
www.azafaros.com

For media inquiries:
Trophic Communications
Eva Mulder and Marie-Theresa Weickert
Email: azafaros@trophic.eu
Phone: +49 (0) 175 222 57 56

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting